Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC

Rhea-AI Summary

Hologic (NASDAQ: HOLX) has entered into an agreement with the CDC to develop analyte specific reagents (ASRs) for detecting H5N1 bird flu. The development comes as H5N1 continues to spread among wild birds, causing outbreaks in poultry and dairy cows in the U.S. The ASRs will be developed on the Panther Fusion® system, with over 1,700 systems installed across U.S. laboratories.

While Hologic doesn't currently plan to commercialize these ASRs, future commercialization may be considered if rapid H5N1 testing becomes necessary. The Panther systems can generate over 1,000 results in 24 hours and can quickly scale up testing capacity. This initiative builds on Hologic's diagnostic solutions portfolio, including their successful COVID-19 testing programs which shipped over 68 million tests to 40 countries in 2020.

Positive

• Strategic partnership with CDC strengthens market position in diagnostic testing
• Extensive installed base of 1,700+ Panther systems across U.S. laboratories
• Demonstrated success in rapid test development (68M COVID tests shipped in 2020)
• Potential future revenue stream if H5N1 testing commercialization becomes necessary

Negative

• No immediate commercial revenue from H5N1 test development
• Investment in R&D required with uncertain return timeline

Insights

Medical Research Analyst

The CDC agreement for H5N1 bird flu test development represents a strategic move in pandemic preparedness. The focus on developing analyte specific reagents (ASRs) for the Panther Fusion® system leverages Hologic's proven molecular testing infrastructure, with over 1,700 systems installed across U.S. laboratories. The platform's capability to process 1,000+ results in 24 hours provides significant scalability advantages.

While currently focused on proof-of-concept development rather than immediate commercialization, this initiative builds on Hologic's successful track record with COVID-19 testing, where they shipped 68 million tests to 40 countries in 2020. The Open Access® functionality allowing labs to develop custom tests could accelerate H5N1 testing deployment if needed, positioning Hologic as a key player in potential outbreak response.

Market Research Analyst

This CDC agreement strengthens Hologic's position in the molecular diagnostics market, particularly in emerging disease surveillance. The company's extensive laboratory network and proven rapid development capabilities, demonstrated during COVID-19, make this a valuable strategic asset. While immediate revenue impact is minimal, the development of H5N1 testing capabilities enhances Hologic's pandemic preparedness portfolio and could provide significant upside if H5N1 testing demand increases.

The integration with existing Panther Fusion® systems means minimal additional infrastructure investment would be needed for deployment, improving potential return on investment. This proactive approach to emerging health threats reinforces Hologic's market leadership in diagnostic solutions and could lead to expanded government partnerships.

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests used to identify specific diseases or conditions — that would aid in the detection of H5N1 bird flu.

Panther Fusion® system (Photo: Business Wire)

H5N1 bird flu, also known as avian influenza A (H5N1), continues to spread among wild birds worldwide and is causing outbreaks in poultry and dairy cows in the U.S., with several recent cases identified in humans who work with these animals.¹ Illness from the virus in the U.S. has been mild but severe illness in other countries has been associated with this virus.² To prepare for if the current outbreak worsens, Hologic will work with the CDC to develop reagents that may be used for H5N1 testing.

“During the COVID-19 pandemic, our teams pivoted rapidly and rose to the challenge of developing critical tests to help curtail the virus’s spread,” said Jennifer Schneiders, Ph.D., President, Diagnostic Solutions. “Hologic’s proven expertise in assay development, innovative instrumentation and extensive reach uniquely position us well to proactively address ever evolving and emerging public health threats.”

The contract will fund proof-of-concept development of ASRs — primers and probes, in this case — that could eventually be incorporated into laboratory-developed tests (LDTs) designed to detect H5N1. While Hologic does not currently intend to make these ASRs commercially available, the company may explore future commercialization should the need for rapid implementation of H5N1 testing arise.

The ASRs are being developed on the Panther Fusion^® system, a fully automated molecular testing platform that allows labs to quickly consolidate and run multiple assays for women's health, infectious disease and SARS-CoV-2 (COVID-19) testing.

The high-throughput Panther^® system has an extensive presence throughout the laboratory community, with more than 1,700 systems installed in public health laboratories, hospitals and private reference laboratories across the U.S. Nearly 500 of the U.S. Panther systems installed are Panther Fusion systems, which can generate over 1,000 results in 24 hours and have the flexibility to rapidly scale up testing capacity without the need for additional instruments or operator training in the event of an outbreak or pandemic.

Hologic’s Open Access^® functionality on the Panther Fusion system also allows labs to develop and automate their own LDTs using a workflow that is easily integrated with U.S. Food and Drug Administration (FDA)-approved in vitro diagnostic (IVD) assay workflows on the system. This can help save time and labor compared with more manual, low-throughput molecular testing workflows.

The development of these ASRs for detection of H5N1 bird flu builds on Hologic’s existing strong portfolio of diagnostic solutions, including assays used for detection of COVID-19. In 2020, Hologic rapidly developed the Panther Fusion^® SARS-CoV-2 assay and the Aptima^® SARS-CoV-2 assay. These tests played a critical role in the global pandemic response, with more than 68 million shipped to 40 countries in 2020 alone. The company continues to innovate in this area, most recently with FDA clearance in 2023 of a test that can detect SARS-CoV-2, influenza A and B, and RSV in a single patient sample.

For more information, please visit www.hologic.com.

About Hologic, Inc.

Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnosis and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X (Twitter), Instagram and YouTube.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

Hologic, The Science of Sure, Aptima, Open Access, Panther and Panther Fusion are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

References

¹ Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. https://www.cdc.gov/bird-flu/situation-summary/index.html
² Centers for Disease Control and Prevention. What Causes Bird Flu Virus Infections in Humans? https://www.cdc.gov/bird-flu/virus-transmission/avian-in-humans.html

SOURCE: Hologic, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241218942183/en/

Media Contact

Bridget Perry

Sr. Director, Corporate Communications

(+1) 508.263.8654

bridget.perry@hologic.com



Investor Contact

Ryan Simon

Vice President, Investor Relations

(+1) 858.410.8514

ryan.simon@hologic.com

Source: Hologic, Inc.

FAQ

What is the purpose of Hologic's agreement with CDC regarding H5N1 testing?

Hologic (HOLX) will develop analyte specific reagents (ASRs) for H5N1 bird flu detection, preparing for potential outbreaks and supporting laboratory-developed tests.

How many Panther testing systems does Hologic have installed in the US?

Hologic has over 1,700 Panther systems installed across U.S. public health laboratories, hospitals, and private reference laboratories, with nearly 500 being Panther Fusion systems.

What is the testing capacity of Hologic's Panther Fusion system?

The Panther Fusion system can generate over 1,000 test results in 24 hours and can rapidly scale up testing capacity without additional instruments or operator training.

Will Hologic's H5N1 test be commercially available?

Currently, Hologic does not intend to make the H5N1 ASRs commercially available, but may explore commercialization if rapid implementation of H5N1 testing becomes necessary.

How many COVID-19 tests did Hologic ship in 2020?

Hologic shipped more than 68 million COVID-19 tests to 40 countries in 2020, demonstrating their capability in rapid test development and distribution.